This article reviews the potential use of a combination of whole-body imaging and targeted contrast agents in improving diagnostics, with a particular focus on oncology imaging. It looks at the rationale for nanoparticles and their development as targeted contrast agents. It subsequently describes many of the advances made thus far in developing tissue-specific contrast agents capable of targeting tumors that combined with whole-body imaging may enable superior cancer detection and characterization.
Paul Foran, Ferdia Bolster, Ian Crosbie, Peter MacMahon, Richard O'Kennedy, and Stephen J Eustace.
Department of Radiology, Mater Misericordiae University Hospital, Dublin, Ireland. paulforan2006@gmail.com
Semin Musculoskelet Radiol. 2010 Mar 1; 14 (1): 86-94.
AbstractThis article reviews the potential use of a combination of whole-body imaging and targeted contrast agents in improving diagnostics, with a particular focus on oncology imaging. It looks at the rationale for nanoparticles and their development as targeted contrast agents. It subsequently describes many of the advances made thus far in developing tissue-specific contrast agents capable of targeting tumors that combined with whole-body imaging may enable superior cancer detection and characterization.Thieme Medical Publishers.